Anti-PD1 Blocking Antibody [3A11]

HUABIO

Anti-PD1 Blocking Antibody [3A11]

7

Flow Cytometry, ELISA

ELISA,FC

Research Use Only

Monoclonal

3A11

2 mg/ml

Unconjugated

PDCD1

programmed cell death 1

ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1, programmed cell death protein 1, programmed cell death 1 protein, protein PD-1, systemic lupus erythematosus susceptibility 2

Mouse

IgG1

Programmed cell death protein 1

PD-1 blockade works during the effector phase to restore the immune function of T cells in the periphery that have been turned off following extended or high levels of antigen exposure, as in advanced cancer. The ligands for PD-1 can be expressed by tumor cells as well as tumor-infiltrating immune cells. PD-L1 expression on tumor cells varies by tumor type and also within a given tumor type, but appears to be particularly abundant in melanoma, non-small cell lung cancer (NSCLC), and ovarian cancer. In a recent study, PD-L1 expression on tumor cells was shown to be significantly associated with PD-1 expression on TILs, and was locally associated with PD-L2 expression when this ligand was also expressed. In the same study, tumor PD-L1 expression was the single factor most closely correlated with response to anti-PD-1 blockade, whereas PD-L1 expression on TILs was not associated with response. patient response to anti-PD-L1 blockade was strongest when PD-L1 was expressed by tumor-infiltrating immune cells. This antibody recognizing the PD-L1 binding region of PD1.

Human

Human

-20°C,2°C to 8°C

41116161